Keya Medical Receives Strategic Investment
February 19, 2020
BEIJING., Feb. 19, 2020 — Beijing Keya Medical Technology Co., Ltd. (Keya Medical), leader in coronary AI technology development, announced today that it has received a strategic investment from Kunlun Wanwei Group, IDG Capital, Shanghai Guofang Parent Fund, and Yahui Capital.
Keya Medical will use this financing round to advance artificial intelligence in medical imaging through product research and development.
Keya Medical has developed the COVID-19 AI Assisted Diagnosis System to aid in the prevention and control of coronavirus disease (COVID-19). The software can quickly provide the auxiliary screening results of COVID-19 through a fully automatic analysis of lung CT. Under the premise of ensuring accuracy, the diagnosis of COVID-19 is significantly improved. Keya Medical has donated the software to hospitals in Hubei, Guangdong, Sichuan, Shandong, and other regions for use.
Keya Medical will continue to use this investment round to accelerate progress in medical imaging AI. Keya Medical welcomes collaboration partners around the world to help support progress.
About Keya Medical
Keya Medical is focused on empowering healthcare with AI-driven quality and productivity innovations. In Jan. 2020, Keya Medical became the first company in China to receive NMPA approval for Class III AI software medical device, DEEPVESSEL FFR. DEEPVESSEL FFR is a non-invasive CT-FFR product that uses deep learning technology to perform a physiological functional assessment of the coronary arteries in minutes from coronary computed tomography angiography scans. For more information, please visit www.deepvessel.net/en.